Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer

Antonio Rossi, Anna La Salvia, Massimo Di Maio

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.

Original languageEnglish
Pages (from-to)171-180
Number of pages10
JournalExpert Review of Respiratory Medicine
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 4 2017

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Drug Therapy
Bibliographic Databases
Appointments and Schedules
Therapeutics
Prospective Studies
gefitinib
Erlotinib Hydrochloride

Keywords

  • Afatinib
  • chemotherapy
  • EGFR
  • erlotinib
  • gefitinib
  • icotinib
  • metastatic
  • mutations
  • NSCLC
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Cite this

Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer. / Rossi, Antonio; La Salvia, Anna; Di Maio, Massimo.

In: Expert Review of Respiratory Medicine, Vol. 11, No. 3, 04.03.2017, p. 171-180.

Research output: Contribution to journalReview article

@article{96d99cc7bbbe420fb92bf98816ee4407,
title = "Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer",
abstract = "Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.",
keywords = "Afatinib, chemotherapy, EGFR, erlotinib, gefitinib, icotinib, metastatic, mutations, NSCLC, tyrosine kinase inhibitor",
author = "Antonio Rossi and {La Salvia}, Anna and {Di Maio}, Massimo",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/17476348.2017.1290526",
language = "English",
volume = "11",
pages = "171--180",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer

AU - Rossi, Antonio

AU - La Salvia, Anna

AU - Di Maio, Massimo

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.

AB - Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.

KW - Afatinib

KW - chemotherapy

KW - EGFR

KW - erlotinib

KW - gefitinib

KW - icotinib

KW - metastatic

KW - mutations

KW - NSCLC

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85013773621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013773621&partnerID=8YFLogxK

U2 - 10.1080/17476348.2017.1290526

DO - 10.1080/17476348.2017.1290526

M3 - Review article

VL - 11

SP - 171

EP - 180

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 3

ER -